Matrix USA Research Upgrades Abraxis Bioscience Inc (ABBI) to Hold
More News related to ABBI
- Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
- Abraxis BioScience (ABBI) Tops Q2 EPS by 5c, Revs Light
- Abraxis BioScience (ABBI) Acquires Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates from Buck Institute
More News related to AZN
- AstraZeneca (AZN) Gets Additional Approval from U.S. FDA for CRESTOR
- US FDA Approves New Indication for CRESTOR(R) (rosuvastatin calcium)
- Atlantis(TM) Patient-Specific Abutment Now Available for NobelActive(TM) Implants
- AstraZeneca (AZN) Biz Unit MedImmune Announces Publication of Pivotal Trial for Motavizumab
- Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
More News related to Upgrades
- Sidoti & Co Upgrades AMCOL International (ACO) to Buy
- Davenport Upgrades Foster Wheeler (FWLT) to Buy; Sell-off is Overdone
- Brean Murray Upgrades Iconix Brand Group (ICON) to Buy
- Brean Murray Upgrades WMS Industries (WMS) to Buy; Attractive Opportunity
- Thomas Weisel Upgrades Agrium (AGU) to Market Weight, Boosts Target to $68
Matrix USA Research upgrades Abraxis Bioscience Inc (Nasdaq: ABBI) from Sell to Hold.
Matrix analyst says, "Increasing demand for injectable drugs resulted in hospital-based revenue growth of 24% during the most recent quarter. ABBI is benefiting from a partnership with AstraZeneca (NYSE: AZN) which is co-promoting Abraxane injectable breast cancer treatment."
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
